Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KCC Peptide Application in the Colon
NCT02156557Phase 1Completed
- Sponsor
- Danielle Kim Turgeon
- Start
- Jun 2014
- Primary completion
- Jul 2016
- Modality
- Light/Condition-Responsive Prodrugs, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of kccfpaq-gggsk-fitc in colorectal cancer (CRC), colon polyp and inflammatory bowel disease (IBD), sponsored by Danielle Kim Turgeon. Primary endpoint: Validation of binding of peptide. Started Jun 2014; status: completed.
02
Drugs
kccfpaq-gggsk-fitc
03
Conditions
colorectal cancer (CRC)colon polypinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT02156557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02156557.